SCHEMBL8293296

SCHEMBL8293296

CCCCCN1CC(C(=O)O)C(C2CC2)C1=O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.47
BACE1 P56817 2/20 0.41
BACE2 Q9Y5Z0 2/20 0.41
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
CNR2 P34972 3/20 0.35
CNR1 P21554 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
CDC25A P30304 1/20 0.34
KCNH2 Q12809 1/20 0.34
PTGER4 P35408 4/20 0.33
PTGER3 P43115 3/20 0.33
PTGER2 P43116 3/20 0.33
BCHE P06276 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8295233 0.94 GBA1 (0.45) GBA1BACE1BACE2ALDH1A1MEN1
SCHEMBL12742684 0.78 GBA1 (0.48) GBA1BACE1BACE2ALDH1A1MEN1
SCHEMBL8293431 0.77 GBA1 (0.50) GBA1BACE1BACE2ALDH1A1MEN1
SCHEMBL14145881 0.75 GBA1 (0.44) GBA1BACE1BACE2ALDH1A1CNR2
SCHEMBL8293428 0.75 GBA1 (0.45) GBA1BACE1BACE2ALDH1A1MEN1
SCHEMBL8292814 0.75 GBA1 (0.43) GBA1BACE1BACE2ALDH1A1MEN1
SCHEMBL14477955 0.74 ELANE (0.44) GBA1BACE1BACE2ALDH1A1MEN1
SCHEMBL12741648 0.74 GBA1 (0.42) GBA1BACE1BACE2ALDH1A1MEN1
SCHEMBL12741650 0.73 GBA1 (0.46) GBA1ALDH1A1MEN1KMT2ACDC25A
SCHEMBL8293994 0.72 BACE1 (0.47) GBA1BACE1BACE2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7910590-B2 Cyclic amine bace-1 inhibitors having a heterocyclic substituent SCHERING CORPORATION (US) 2011-03-22 US disclosed
US-7910590-B2 Cyclic amine bace-1 inhibitors having a heterocyclic substituent SCHERING CORPORATION (US) 2011-03-22 US disclosed
US-20090312341-A1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT SCHERING CORPORATION 2009-12-17 US disclosed
US-20090312341-A1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT SCHERING CORPORATION 2009-12-17 US disclosed
US-7598250-B2 Cyclic amine BACE-1 inhibitors having a heterocyclic substituent SCHERING CORPORATION (US) 2009-10-06 US disclosed
US-7598250-B2 Cyclic amine BACE-1 inhibitors having a heterocyclic substituent SCHERING CORPORATION (US) 2009-10-06 US disclosed
EP-1660447-B1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT SCHERING CORP (US) 2008-07-30 EP disclosed
WO-2005014540-A1 CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT SCHERING CORPORATION (US) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312341-A1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT BACE1, BACE2, PSEN1 GBA1 15/4885BACE1 1/4885BACE2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.